This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (226)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in JAMA  Topic Collections  • Renal Diseases  • Renal Diseases, Other  • Alert me on articles by topic

Robert J. Motzer, MD; Brian I. Rini, MD; Ronald M. Bukowski, MD; Brendan D. Curti, MD; Daniel J. George, MD; Gary R. Hudes, MD; Bruce G. Redman, DO; Kim A. Margolin, MD; Jaime R. Merchan, MD; George Wilding, MD; Michelle S. Ginsberg, MD; Jennifer Bacik, MS; Sindy T. Kim, BS; Charles M. Baum, MD, PhD; M. Dror Michaelson, MD, PhD

JAMA. 2006;295:2516-2524.

Context  Current treatment options for metastatic renal cell carcinoma (RCC) are limited and there is a need to identify novel and effective therapies. Sunitinib malate is an oral multitargeted tyrosine kinase inhibitor, which has shown activity in an initial study of cytokine-refractory metastatic RCC patients.

Objective  To confirm the antitumor efficacy of sunitinib as second-line treatment in patients with metastatic clear-cell RCC, the predominant cell type of this malignancy.

Design, Setting, and Patients  Open-label, single-arm, multicenter clinical trial. Patients were enrolled between February and November 2004, with follow-up continuing until disease progression, unacceptable toxicity, or withdrawal of consent. The reported data apply through August 2005. Patients (N = 106) had metastatic clear-cell RCC, which had progressed despite previous cytokine therapy.

Intervention  Repeated 6-week cycles of sunitinib, 50 mg per day given orally for 4 consecutive weeks followed by 2 weeks off per treatment cycle.

Main Outcome Measures  Assessment of clinical response, degree of tumor regression on imaging studies using the Response Evaluation Criteria in Solid Tumors (RECIST) guidelines. Primary end point was overall objective response rate (complete plus partial). Secondary end points were progression-free survival and safety. Response was evaluated by independent third-party core imaging laboratory and by treating physicians (investigator assessment).

Results  All 106 patients received sunitinib and were included in the intent-to-treat population for safety analyses. Of these, 105 patients were evaluable for efficacy analyses. The objective response rate according to an independent third-party assessment resulted in 36 patients with partial response (34%; 95% confidence interval, 25%-44%), and a median progression-free survival of 8.3 months (95% confidence interval, 7.8-14.5 months). The most common adverse events experienced by patients were fatigue in 30 (28%) and diarrhea 21 (20%). Neutropenia, elevation of lipase, and anemia were the most common laboratory abnormalities observed in 45 (42%), 30 (28%), and 27 (26%) patients, respectively.

Conclusion  The results of this trial demonstrate the efficacy and manageable adverse-event profile of sunitinib as a single agent in second-line therapy for patients with cytokine-refractory metastatic clear-cell RCC.

Trial Registration  clinicaltrials.gov Identifier: NCT00077974

Author Affiliations: Departments of Medicine (Dr Motzer), Radiology (Dr Ginsberg), and Biostatistics and Epidemiology (Ms Bacik), Memorial Sloan-Kettering Cancer Center, New York, NY; Department of Medicine, University of California, San Francisco (Dr Rini); Experimental Therapeutics Program, Cleveland Clinic Foundation, Cleveland, Ohio (Dr Bukowski); The Earle A. Chiles Research Institute, Robert W. Franz Cancer Center, Portland, Ore (Dr Curti); Department of Medicine, Division of Medical Oncology, Duke University Medical Center, Durham, NC (Dr George); Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, Pa (Dr Hudes); Department of Internal Medicine, University of Michigan, Ann Arbor (Dr Redman); Division of Medical Oncology, City of Hope National Medical Center, Duarte, Calif (Dr Margolin); Department of Oncology, Mayo Clinic, Rochester, Minn (Dr Merchan); Department of Medicine, University of Wisconsin Comprehensive Cancer Center, Madison (Dr Wilding); Oncology Clinical Development, Pfizer Inc, La Jolla, Calif (Ms Kim and Dr Baum); Department of Hematology/Oncology, Massachusetts General Hospital, Boston (Dr Michaelson). Dr Rini is now with the Cleveland Clinic Foundation, Cleveland, Ohio.

RELATED ARTICLE

A New Strategy in the War on Renal Cell Cancer: Hitting Multiple Targets With Limited Collateral Damage
Boris Pasche
JAMA. 2006;295(21):2537-2538.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Combination of Quantitative IMP3 and Tumor Stage: A New System to Predict Metastasis for Patients with Localized Renal Cell Carcinomas
Jiang et al.
Clin. Cancer Res. 2008;14:5579-5584.
ABSTRACT | FULL TEXT  

Secondary Erythrocytosis Produced by the Tyrosine Kinase Inhibitors Sunitinib and Sorafenib
Alexandrescu et al.
JCO 2008;26:4047-4048.
FULL TEXT  

Antitumor Activity and Biomarker Analysis of Sunitinib in Patients With Bevacizumab-Refractory Metastatic Renal Cell Carcinoma
Rini et al.
JCO 2008;26:3743-3748.
ABSTRACT | FULL TEXT  

What is the risk of intracranial bleeding during anti-VEGF therapy?
Carden et al.
Neuro Oncol 2008;10:624-630.
ABSTRACT | FULL TEXT  

Palmar-Plantar Erythrodysesthesia Secondary to Sunitinib Treatment Resulting in Necrotic Foot Syndrome Aggravated by Background Diabetic Vascular Disease
Guenova et al.
Arch Dermatol 2008;144:1081-1082.
FULL TEXT  

Soluble receptor-mediated selective inhibition of VEGFR and PDGFR{beta} signaling during physiologic and tumor angiogenesis
Kuhnert et al.
Proc. Natl. Acad. Sci. USA 2008;105:10185-10190.
ABSTRACT | FULL TEXT  

Activity of Sunitinib in Patients With Advanced Neuroendocrine Tumors
Kulke et al.
JCO 2008;26:3403-3410.
ABSTRACT | FULL TEXT  

Stability of Sunitinib in Oral Suspension
Navid et al.
The Annals of Pharmacotherapy 2008;42:962-966.
ABSTRACT | FULL TEXT  

Sorafenib, but not sunitinib, affects function of dendritic cells and induction of primary immune responses
Hipp et al.
Blood 2008;111:5610-5620.
ABSTRACT | FULL TEXT  

Case 17-2008 -- A 63-Year-Old Man with Metastatic Renal-Cell Carcinoma
Michaelson et al.
NEJM 2008;358:2389-2396.
FULL TEXT  

Transient Sunitinib-Induced Coma in a Patient With Fibromyxoid Sarcoma
Arnaud et al.
JCO 2008;26:1569-1571.
FULL TEXT  

Is Anemia of Cancer Different From Chemotherapy-Induced Anemia?
Steensma
JCO 2008;26:1022-1024.
FULL TEXT  

Commentary: Novel Therapies for Cancer: Why Dirty Might Be Better
Fojo
The Oncologist 2008;13:277-283.
FULL TEXT  

Multicenter, Phase II Trial of Sunitinib in Previously Treated, Advanced Non-Small-Cell Lung Cancer
Socinski et al.
JCO 2008;26:650-656.
ABSTRACT | FULL TEXT  

Small Molecules: Big Changes in the Cancer Treatment Paradigm
Garcia
Journal of Pharmacy Practice 2008;21:17-35.
ABSTRACT  

Role of sunitinib and sorafenib in the treatment of metastatic renal cell carcinoma
Hiles and Kolesar
Am J Health Syst Pharm 2008;65:123-131.
ABSTRACT | FULL TEXT  

Renal Cell Carcinoma: New Developments in Molecular Biology and Potential for Targeted Therapies
Costa and Drabkin
The Oncologist 2007;12:1404-1415.
ABSTRACT | FULL TEXT  

Review: Side Effects of Approved Molecular Targeted Therapies in Solid Cancers
Widakowich et al.
The Oncologist 2007;12:1443-1455.
ABSTRACT | FULL TEXT  

Phase 2 Study of ABT-510 in Patients with Previously Untreated Advanced Renal Cell Carcinoma
Ebbinghaus et al.
Clin. Cancer Res. 2007;13:6689-6695.
ABSTRACT | FULL TEXT  

Best Cases from the AFIP: Metastatic Renal Cell Carcinoma
Lin et al.
RadioGraphics 2007;27:1801-1807.
FULL TEXT  

Phase II Trial of Sunitinib in Patients With Metastatic Colorectal Cancer After Failure of Standard Therapy
Saltz et al.
JCO 2007;25:4793-4799.
ABSTRACT | FULL TEXT  

Reversible cognitive disorders after sunitinib for advanced renal cell cancer in patients with preexisting arteriosclerotic leukoencephalopathy
van der Veldt et al.
Ann Oncol 2007;18:1747-1750.
FULL TEXT  

Treatment of metastatic renal cancer with capsid-modified oncolytic adenoviruses
Guse et al.
Molecular Cancer Therapeutics 2007;6:2728-2736.
ABSTRACT | FULL TEXT  

Pseudohypoxic Pathways in Renal Cell Carcinoma
Bratslavsky et al.
Clin. Cancer Res. 2007;13:4667-4671.
ABSTRACT | FULL TEXT  

Imaging in Metastatic Renal Cell Carcinoma
Griffin et al.
Am. J. Roentgenol. 2007;189:360-370.
ABSTRACT | FULL TEXT  

Hypertension, Proteinuria, and Antagonism of Vascular Endothelial Growth Factor Signaling: Clinical Toxicity, Therapeutic Target, or Novel Biomarker?
van Heeckeren et al.
JCO 2007;25:2993-2995.
FULL TEXT  

Complete cerebral response with sunitinib for metastatic renal cell carcinoma
Medioni et al.
Ann Oncol 2007;18:1282-1283.
FULL TEXT  

CCR Drug Updates: Sorafenib and Sunitinib in Renal Cell Carcinoma
Stein and Flaherty
Clin. Cancer Res. 2007;13:3765-3770.
FULL TEXT  

Design of Clinical Trials of Radiation Combined with Antiangiogenic Therapy
Senan and Smit
The Oncologist 2007;12:465-477.
ABSTRACT | FULL TEXT  

Chromosomes, Hypoxia, Angiogenesis, and Trial Design: A Brief History of Renal Cancer Drug Development
Stadler
Clin. Cancer Res. 2007;13:1630-1633.
FULL TEXT  

Sunitinib (Sutent(R)): A novel agent for the treatment of metastatic renal cell carcinoma
Chouhan et al.
J Oncol Pharm Pract 2007;13:5-15.
ABSTRACT  

Recent Progress in the Management of Advanced Renal Cell Carcinoma
Garcia and Rini
CA Cancer J Clin 2007;57:112-125.
ABSTRACT | FULL TEXT  

Vascular Endothelial Growth Factor-Targeted Therapy in Renal Cell Carcinoma: Current Status and Future Directions
Rini
Clin. Cancer Res. 2007;13:1098-1106.
ABSTRACT | FULL TEXT  

Small Molecule Tyrosine Kinase Inhibitors in the Treatment of Solid Tumors: An Update of Recent Developments
Steeghs et al.
Ann. Surg. Oncol. 2007;14:942-953.
ABSTRACT | FULL TEXT  

Prognostic factors associated with long-term survival in previously untreated metastatic renal cell carcinoma
Choueiri et al.
Ann Oncol 2007;18:249-255.
ABSTRACT | FULL TEXT  

Vascular Endothelial Growth Factor Gene Polymorphisms Are Associated with Prognosis in Ovarian Cancer
Hefler et al.
Clin. Cancer Res. 2007;13:898-901.
ABSTRACT | FULL TEXT  

Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma
Motzer et al.
NEJM 2007;356:115-124.
ABSTRACT | FULL TEXT  

Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma
Escudier et al.
NEJM 2007;356:125-134.
ABSTRACT | FULL TEXT  

Hypothyroidism in Patients With Metastatic Renal Cell Carcinoma Treated With Sunitinib
Rini et al.
JNCI J Natl Cancer Inst 2007;99:81-83.
ABSTRACT | FULL TEXT  

Two Distinct Types of Blood Vessels in Clear Cell Renal Cell Carcinoma Have Contrasting Prognostic Implications
Yao et al.
Clin. Cancer Res. 2007;13:161-169.
ABSTRACT | FULL TEXT  

Targeting von Hippel-Lindau Pathway in Renal Cell Carcinoma
Patel et al.
Clin. Cancer Res. 2006;12:7215-7220.
ABSTRACT | FULL TEXT  

Immunotherapy for Renal Cell Cancer
Yang and Childs
JCO 2006;24:5576-5583.
ABSTRACT | FULL TEXT  

Targeted Therapy for Metastatic Renal Cell Carcinoma
Motzer and Bukowski
JCO 2006;24:5601-5608.
ABSTRACT | FULL TEXT  

Respecting cancer drug transportability: a basis for successful lead selection.
Sausville
JNCI J Natl Cancer Inst 2006;98:1098-1099.
FULL TEXT  

A new strategy in the war on renal cell cancer: hitting multiple targets with limited collateral damage.
Pasche
JAMA 2006;295:2537-2538.
FULL TEXT